This study explores the effectiveness of RP-1664, a selective oral inhibitor of polo-like kinase 4 (PLK4), targeting adult and adolescent patients with TRIM37-high solid tumors.

Theratechnologies Inc. has achieved a significant milestone in its Phase 1 clinical trial for sudocetaxel zendusortide.

Neurophth Therapeutics has successfully enrolled the final participant in its Phase I/II clinical study of Opvika® (Esonadogene Imvoparvovec), a treatment for Leber hereditary optic neuropathy (LHON) caused by the ND4 gene mutation.

Tharimmune, Inc. has successfully completed a Phase 1 clinical trial for TH104, a transmucosal buccal film containing nalmefene, which is well-tolerated with mild side effects.

Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).

Immune-Onc Therapeutics has entered into a clinical trial collaboration with Roche to assess the potential of IO-108 as a first-line treatment for hepatocellular carcinoma (HCC).

NextPoint Therapeutics has initiated a Phase 1 clinical trial for NPX887, a drug designed to target solid tumors with high expression of the HHLA2/B7-H7 antigen.

Monopar Therapeutics Inc. has been given the green light by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 dosimetry study for its innovative radiopharmaceutical, MNPR-101-Zr.

Arvinas Inc. has initiated its Phase 1 clinical trial of ARV-102, a novel oral PROTAC® protein degrader aimed at treating neurodegenerative diseases.

Aleta Biotherapeutics, a company specializing in immuno-oncology, has initiated a Phase 1/2 clinical trial for its innovative biologic, ALETA-001.

ReCode Therapeutics, a company specializing in genetic medicine, has initiated a Phase 1 clinical trial for RCT2100, an innovative inhaled treatment for cystic fibrosis (CF).

The study focused on the use of paxalisib, an oral medication that inhibits both PI3K and mTOR, alongside radiation therapy for patients with brain metastases from solid tumors that have a PI3K pathway mutation.